De Novo Sequencing of Antibody Light Chain Proteoforms from Patients with Multiple Myeloma

07 May 2021, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

In multiple myeloma diseases, monoclonal immunoglobulin light chains (LC) are abundantly produced, with the consequence in some cases to form deposits affecting various organs, such as kidney, while in other cases to remain soluble up to concentrations of several g.L-1 in plasma. The exact factors crucial for the solubility of light chains are poorly understood, but it can be hypothesized that their amino acid sequence plays an important role. Determining the precise sequences of patient-derived light chains is therefore highly desirable. We establish here a novel de novo sequencing workflow for patient-derived LCs, based on the combination of bottom-up and top-down proteomics without database search. This pipeline is then used for the complete de novo sequencing of LCs extracted from the urine of 10 patients with multiple myeloma. We show that for the bottom-up part, digestions with trypsin and Nepenthes fluid extract are sufficient to produce overlapping peptides able to generate the best sequence candidates. For the sequencing of intact LC proteoforms, combining activation methods is key to achieve single amino acid resolution.

Keywords

antibody
Light chain disease
Proteoforms
de novo sequencing
bottom-up proteomics
top-down proteomics

Supplementary materials

Title
Description
Actions
Title
2021 Denovo LC Analchem 20210505 final
Description
Actions
Title
2021 Denovo LC Analchem 20210505 SI final
Description
Actions
Title
2021 Denovo LC Analchem Tables 20210505 SI final
Description
Actions
Title
2021 Denovo LC Analchem parameters-SSbond search
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.